Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02798406
Title Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)
Acronym CAPTIVE
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors DNAtrix, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Arkansas for Medical Sciences (UAMS) Little Rock Arkansas 72205 United States Details
UCLA Medical Center Los Angeles California 90095 United States Details
Northwestern University Chicago Illinois 60611 United States Details
University of Minnesota Neurosurgery Minneapolis Minnesota 55455 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Weill-Cornell Medicine New York-Presbyterian New York New York 10065 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27514 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
Ohio State University James Cancer Center Columbus Ohio 43210 United States Details
Lehigh Valley Health Network Allentown Pennsylvania 18103 United States Details
Texas Oncology Austin-Midtown Austin Texas 78705 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
University Health Network Toronto Ontario M5T 2S8 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field